process-instructed self neuro-modulation (prism) for attention deficit/ hyperactivity disorder - adults

Conditions: Attention Deficit Hyper Activity

Summary: this is a single-arm, open-label feasibility study. participants will be assigned and will undergo a novel neurofeedback intervention, targeting down-regulation of deep limbic structures, specifically the amygdalae. participants will complete 12 neurofeedback sessions delivered twice weekly over 6 consecutive weeks. the intervention will be delivered via the prism platform.

the objectives include: 1)training the nyu team on the electric finger print electroencephalography neurofeedback (efp-eeg-nf) technology and provide them with hands-on experience; 2) assessing participants' ability to learn the feedback paradigm (i.e. control the efp-eeg-nf signal; time to achieve learning; assess learning curves); 3) exploring preliminary results assessing target symptoms (e.g. aisrs and brief-a).

Eligibility criteria:
inclusion criteria: * adults ages 18-60 years, inclusive at the time of consent * able to provide signed informed consent * any gender * subjects with a current primary dsm-5 diagnosis of adhd (including predominantly inattentive presentation, hyperactive presentation, or combined presentations) as confirmed by the acds version 1.2. * subjects who are not receiving any pharmacological treatment for adhd must have an aisrs score of ≥ 28 at screening. subjects who are receiving pharmacological treatment for adhd at screening must have a minimum aisrs score of ≥ 22 at screening * not requiring treatment for any comorbid psychiatric condition for at least 2 months * normal or corrected-to-normal vision * normal or corrected-to-normal hearing * no intention of changing medication or psychotherapy for the duration of the study at the time of recruitment exclusion criteria: * concurrent substance abuse and/or history of substance use within 6 months * use of any prescribed benzodiazepine * lifetime bipolar disorder, psychotic disorder, autism, intellectual disability. comorbid mood and anxiety disorders determined by the mini will be permitted if they are not the primary focus of clinical attention * active suicidality within past year, or history of suicide attempt in past 2 years * any history of severe past drug dependence determined by the mini (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty) * any unstable medical or neurological condition * any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury \[tbi\] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days) * any psychotropic medication * recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based ptsd psychotherapy (cognitive processing therapy \[cpt\], prolonged exposure \[pe\], eye movement desensitization and reprocessing \[emdr\]); continuation of established maintenance supportive therapy will be permitted * significant hearing loss or severe sensory impairment * enrollment in another research study testing an experimental, clinical, or behavioral intervention intended to affect symptoms initiated within the last 2 months, or intended enrollment within the next 2.5 months

Keywords: prism